This Marijuana Giant Is 'Ticking All The Right Boxes' For Long-Term Success, Analyst Says

Tilray Brands, Inc. TLRY released on Monday its financial results for Q2 2023, revealing net revenue of $144.1 million, a 7% decrease compared to $155.2 million in Q2 2022.

Gross profit rose to $40.1 million, a 22% increase, year-over-year. Adjusted gross margin held at 29% compared to the year-ago quarter. The cannabis giant achieved $119.6 million in annualized cash cost-savings since the closing of the Tilray-Aphria transaction in May 2021 - up from $108 million as of August 31, 2022.

For the period, Tilray also reported adjusted EBITDA of $11.7 million, a 15% decrease compared to $13.8 million in Q2 2022. This was its 15th consecutive quarter of positive adjusted EBITDA.

Net loss was $61.6 million, compared to net income of $5.8 million in Q2 2022.

The Analyst

Following the report, Cantor Fitzgerald’s Pablo Zuanic maintained a ‘Neutral’ rating on Tilray's stock, reducing the price target from $4.50 to $3.65.

The Thesis 

The analyst lowered the price target to address reduced estimates and sectoral derating. 

In the long term view, Tilray is ticking “all the right boxes” said Zuanic, referring to how the company is number one in the domestic recreational market, as well as in Europe, while also being focused on developing a CPG brand portfolio that could one day overlap with marijuana. 

Tilray reaffirmed EBITDA guidance of $70-80 million for the fiscal year ending May 2023, but Zuanic projects $62 million. 

Tilray's Priorities

The analyst noted that the company’s leadership is aware of difficult times for the industry, and is thus focused on cost savings (across divisions and regions, and is finding original ways of using capacity), improving cash flow, and maintaining a strong balance sheet.

“Remaining on Nasdaq remains priority for the company, so management hinted it will not consider Canopy Growth’s CGC strategy of potentially delisting and only having a TSX listing.”

Zuanic wants 50% upside for the stock to get an ‘Overweight’ rating; that’s why he is staying ‘Neutral’ on Tilray's stock.

Among other Canadian cannabis companies, Zuanic only rates Aurora Cannabis ACB and Village Farms VFF as ‘Overweight.’

The Price Action 

Tilray shares were trading flat at $3.04 per share at the time of writing Thursday morning. 

Photo: Courtesy of Harrison Haines via Pexels

 

TLRY Logo
TLRYTilray Brands Inc
$0.4638-4.47%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
3.23
Growth
1.29
Quality
-
Value
81.09
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Posted In:

Cannabis is evolving—don’t get left behind!

Curious about what’s next for the industry and how to stay ahead in today’s competitive market?

Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.

Secure your spot now before prices go up—this is where the biggest deals and connections happen!

Get your tickets today!

Comments
Loading...